The Progress and Controversial of the Use of Beta Blockers in Patients with Heart Failure with a Preserved Ejection Fraction

Overview

Journal Int J Cardiol Heart Vasc

Date 2019 Dec 31

PMID 31886405

Citations 9

Authors

Xizhen Xu

Dao Wen Wang

Affiliations

Soon will be listed here.

Abstract

Beta blockers are a recommended therapy in patients with heart failure with reduced ejection fraction(HFrEF). Beta blockers markedly and unequivocally reduce mortality in patients with heart failure with reduced ejection fraction. However, the beneficial effects of beta blockers in patients with heart failure with preserved ejection fraction(HFpEF) are not well established. In this review, we will assess the evidence basis of the recommendations for beta blockers and discuss emerging concerns about the use of beta blockers in patients with HFpEF. The available evidence for beta blockers is limited and it remains uncertain whether beta blockers have a beneficial role in the treatment of HFpEF in the absence of an alternative indication for their use.

Citing Articles

One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing.

Gosciniak A, Stasilowicz-Krzemien A, Michniak-Kohn B, Fiedor P, Cielecka-Piontek J Molecules. 2024; 29(12).

PMID: 38931002 PMC: 11206936. DOI: 10.3390/molecules29122938.

Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon.

Luca F, Oliva F, Abrignani M, Di Fusco S, Gori M, Giubilato S J Clin Med. 2024; 13(5).

PMID: 38592244 PMC: 10933980. DOI: 10.3390/jcm13051375.

Predictors of Premature Mortality Following Coronary Artery Bypass Grafting: An Iranian Single-Centre Study.

Pakrad F, Shiri R, Mozayani Monfared A, Mohammadi Saleh R, Poorolajal J Healthcare (Basel). 2024; 12(1).

PMID: 38200942 PMC: 10779296. DOI: 10.3390/healthcare12010036.

Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.

Wu M, Ni D, Huang L, Qiu S Clin Cardiol. 2023; 46(8):845-852.

PMID: 37272188 PMC: 10436801. DOI: 10.1002/clc.24058.

Investigating the effects of beta-blockers on circadian heart rhythm using heart rate variability in ischemic heart disease with preserved ejection fraction.

Saleem S, Khandoker A, Alkhodari M, Hadjileontiadis L, Jelinek H Sci Rep. 2023; 13(1):5828.

PMID: 37037871 PMC: 10086029. DOI: 10.1038/s41598-023-32963-0.

References

Patterson A, Zhu W, Chow A, Agrawal R, Kosek J, Xiao R . Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart. Crit Care Med. 2004; 32(4):1041-8. DOI: 10.1097/01.ccm.0000120049.43113.90. View

Yamamoto K . β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. J Cardiol. 2015; 66(3):189-94. DOI: 10.1016/j.jjcc.2015.02.004. View

Zhang R, Khoo M, Wu Y, Yang Y, Grueter C, Ni G . Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11(4):409-17. DOI: 10.1038/nm1215. View

Huang J, Li C, Song Y, Fan X, You L, Tan L . ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure. Cell Discov. 2018; 4:57. PMC: 6198009. DOI: 10.1038/s41421-018-0058-6. View

Liggett S, Wagoner L, Craft L, Hornung R, Hoit B, McIntosh T . The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998; 102(8):1534-9. PMC: 509003. DOI: 10.1172/JCI4059. View

Hernandez A, Hammill B, OConnor C, Schulman K, Curtis L, Fonarow G . Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009; 53(2):184-92. PMC: 3513266. DOI: 10.1016/j.jacc.2008.09.031. View

Tsioufis C, Georgiopoulos G, Oikonomou D, Thomopoulos C, Katsiki N, Kasiakogias A . Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots. Curr Vasc Pharmacol. 2017; 16(1):15-22. DOI: 10.2174/1570161115666170414120532. View

Yamamoto K, Origasa H, Hori M . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2012; 15(1):110-8. DOI: 10.1093/eurjhf/hfs141. View

Borlaug B, Redfield M . Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011; 123(18):2006-13. PMC: 3420141. DOI: 10.1161/CIRCULATIONAHA.110.954388. View

10.

Butler J, Fonarow G, Zile M, Lam C, Roessig L, Schelbert E . Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014; 2(2):97-112. PMC: 4028447. DOI: 10.1016/j.jchf.2013.10.006. View

11.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

12.

Redfield M, Anstrom K, Levine J, Koepp G, Borlaug B, Chen H . Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015; 373(24):2314-24. PMC: 4712067. DOI: 10.1056/NEJMoa1510774. View

13.

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice.... Circulation. 2011; 123(10):e269-367. DOI: 10.1161/CIR.0b013e318214876d. View

14.

Flather M, Shibata M, Coats A, Van Veldhuisen D, Parkhomenko A, Borbola J . Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3):215-25. DOI: 10.1093/eurheartj/ehi115. View

15.

Lund L, Benson L, Dahlstrom U, Edner M, Friberg L . Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014; 312(19):2008-18. DOI: 10.1001/jama.2014.15241. View

16.

Cleland J, Bunting K, Flather M, Altman D, Holmes J, Coats A . Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2017; 39(1):26-35. PMC: 5837435. DOI: 10.1093/eurheartj/ehx564. View

17.

Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T . Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail. 2008; 10(5):446-53. DOI: 10.1016/j.ejheart.2008.03.002. View

18.

Messerli F, Rimoldi S, Bangalore S . The Transition From Hypertension to Heart Failure: Contemporary Update. JACC Heart Fail. 2017; 5(8):543-551. DOI: 10.1016/j.jchf.2017.04.012. View

19.

Kotecha D, Flather M, Altman D, Holmes J, Rosano G, Wikstrand J . Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol. 2017; 69(24):2885-2896. DOI: 10.1016/j.jacc.2017.04.001. View

20.

Ulimoen S, Enger S, Pripp A, Abdelnoor M, Arnesen H, Gjesdal K . Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2013; 35(8):517-24. DOI: 10.1093/eurheartj/eht429. View